World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
78
Citations
50250
World Ranking
1247
National Ranking
552

Medicine

D-Index
83
Citations
54029
World Ranking
15338
National Ranking
7734

Walter J. Urba publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Walter J. Urba sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 265 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Walter J. Urba D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Walter J. Urba sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 78 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Walter J. Urba is affiliated with Providence Portland Medical Center in the United States. Their research spans multiple areas within medicine, biochemistry, genetics, and molecular biology, with significant contributions focused on oncology, molecular biology, immunology, infectious diseases, and pulmonary and respiratory medicine.

The scientist's main topics of work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • SARS-CoV-2 and COVID-19 Research
  • Vaccines and immunoinformatics approaches

Among the recent publications associated with Walter J. Urba are:

  • "Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer" (2022) in the New England Journal of Medicine
  • "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134" (2022) in the Journal of Clinical Oncology
  • "Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma" (2020) in Cancer Cell
  • "Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma" (2021) in the Journal for ImmunoTherapy of Cancer
  • "Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells" (2021) in Nature Communications

Frequent coauthors who have collaborated extensively with Walter J. Urba include:

  • William L. Redmond
  • Rom S. Leidner
  • Brian Piening
  • Carlo Bifulco
  • Yoshinobu Koguchi

Walter J. Urba's work has been published frequently in venues such as:

  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)

The scientist's research primarily falls within the fields of Medicine and Biochemistry, Genetics, and Molecular Biology with a heavy emphasis on applied oncology and immunological responses related to cancer treatment and immunotherapy developments.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

    Nadeem Riaz;Jonathan J. Havel;Vladimir Makarov;Alexis Desrichard

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

    André Kahles;Kjong-Van Lehmann;Nora C Toussaint;Matthias Hüser

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

    S.E. Jones;J. Erban;B. Overmoyer;G.T. Budd

  • Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

    Matthew H. Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • OX40 is a potent immune-stimulating target in late-stage cancer patients.

    Brendan D. Curti;Magdalena Kovacsovics-Bankowski;Nicholas Morris;Edwin Walker

  • Phase I/II study of ipilimumab for patients with metastatic melanoma

    Jeffrey S. Weber;Steven O’Day;Walter Urba;John Powderly

  • Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

    Unknown

  • Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

    Andrew D. Weinberg;Martin Muy Rivera;Rodney Prell;Arden Morris

  • Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

    Unknown

  • Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.

    D L Longo;P L Duffey;R C Young;S M Hubbard

  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

    Franz X. Schaub;Varsha Dhankani;Ashton C. Berger;Mihir Trivedi

  • Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

    Joseph I. Clark;Michael B. Atkins;Walter J. Urba;Steven Creech

  • Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

    Steven J. O'Day;Omid Hamid;Walter J. Urba

  • Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Jedd D. Wolchok;F. Stephen Hodi;Jeffrey S. Weber;James P. Allison

  • Exacerbation of symptoms of autoimmune disease in patients receiving alpha‐interferon therapy

    Kevin C. Conlon;Walter J. Urba;John W. Smithii;Ronald G. Steis

  • Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Neil H Segal;Theodore F Logan;F. Stephen Hodi;David F. McDermott

Frequent Co-Authors

Bernard A. FoxEarle
Bernard A. FoxEarle Earle A. Chiles Research Institute
Dan L. Longo
Dan L. Longo Harvard University
F. Stephen Hodi
F. Stephen Hodi Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Steven J. O'Day
Steven J. O'Day St. John's University
Mario Sznol
Mario Sznol Yale University
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Jeffrey W. Clark
Jeffrey W. Clark Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in microbiology, expanding your education through related online degrees can open diverse career opportunities. Many students explore online medical programs to gain foundational knowledge that complements microbiology careers in healthcare and research.

Public health is another vital field connected to microbiology. If you’re seeking flexible learning options, exploring which online mph programs are easiest to get into can help you identify accessible routes to becoming a public health professional focused on disease control and prevention.

Specialized roles such as a child life specialist combine science with patient care, emphasizing support for young patients and families. To understand potential earnings, consider reviewing information about child.life specialist salary.

Additionally, for individuals with unique backgrounds, including those with criminal records, education remains attainable. The best degrees for felons list highlights inclusive online programs that can help broaden career prospects in microbiology-related fields.

Best Scientists Citing Walter J. Urba

Trending Scientists

Recently Published Articles